Evidence Table 100.KQ 3—Continuous Creatinine

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **CVD****Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome / Unit of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD /****P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lee200836Parallel | At high risk for CHD | Warfarin | 3.5 | Ginseng | 12 | NRUnit: mg/dl | Mean: 0.74SD: 0.19 | Mean:-0.04 | NR: | There were no statistically significant differences between the ginseng group and control group. | N/A |
| No Treatment | 13 | Mean:0.86SD: 0.21 | Mean:-0.01SD:0.8 |
| Nordøy200054Parallel | Mixed: Low and/or mod to high risk | Simvastatin | 20 | Omega-3 |  | NRUnit: NR | NR | NR | NR | no significant changes were observed in serum creatinine levels | Medium |
| Placebo |  | NR | NR |
| Napoli199852Parallel | Unclear | Pravastatin | 20-40 | Vitamin E |  | NRUnit: NR | NR | NR | NR | No differences in routine laboratory tests or adverse events were registered during the study (data not shown); in particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups.” | Medium |
| No Treatment |  | NR | NR |
| Reyes198459Parallel | Mixed:Low and/or Moderate | Hydrochlorothiazide | 50 | Magnesium | 13 | NRUnit: NR | NR | P: NS | NR | Results state only that 'no statistically significant changes affected the electrocardiogram or the plasma variables studied during the trial'. | Medium |
| Placebo | 8 | NR | P: NS |
| Budoff200410Parallel | At high risk for CHD | Statins + aspirin | 10-40 | Garlic | 9 | Measured after 12 hr fastUnit: mg/dl | NR | Mean: 0SD: 0 | P:0.9152 | N/A | Medium |
| Placebo | 10 | NR | Mean: 0.01SD: 0.14 |

Evidence Table 100.KQ 3—Continuous Creatinine (continued)

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **CVD****Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome / Unit of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD /****P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Wolf200868Crossover | Mixed:Low and/or Moderate | ASA | 500 | Gingko biloba |  | NRUnit: NR | NR | NR | NR | Study states that: Laboratory findings in all subjects were un-remarkable and did not indicate any differences between the treatment groups. | Low-medium |
|  |  | NR | NR |
| De Caterina200216Crossover | At high risk for CHD | Simvastatin | 10-40 | Vitamin E |  | NRUnit: pg/mg | Mean: 237SD: 122 | NR | NR | N/A | High |
| No treatment |  | Mean: 240SD: 124 | NR |